Doxycycline Hyclate

Product NDC
24658-310
11-digit product format
246580310
Labeler code
24658
Product ID
24658-310_65cac0b6-3550-48cf-bffa-cf42443c2731
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Doxycycline Hyclate
Dosage form
TABLET, FILM COATED
Route
ORAL
Labeler
PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS
Application
ANDA062269
Marketing category
ANDA
Marketing start
2025-03-07
Substance
DOXYCYCLINE HYCLATE
Active strength
100 mg/1
Pharmacologic classes
Tetracycline-class Drug [EPC], Tetracyclines [CS]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062269-002DOXYCYCLINE HYCLATEDOXYCYCLINE HYCLATEEQ 100MG BASETABLET / ORALABRS1982-11-08
A062269-003DOXYCYCLINE HYCLATEDOXYCYCLINE HYCLATEEQ 50MG BASETABLET / ORALAB1983-10-05

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A062269-002AB
A062269-003AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Doxycycline HyclateDOXYCYCLINE HYCLATEPURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS65cac0b6-3550-48cf-bffa-cf42443c27312025-04-14Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline hyclate tablets, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing use of antibacterial drugs not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. Fixed drug eruptions have occurred with doxycycline and have been associated with worsening severity upon subsequent administrations, including generalized bullous fixed drug eruption (See ADVERSE REACTIONS .) If severe skin reactions occur, discontinue doxycycline hyclate tablets immediately and institute appropriate therapy. Intr...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS Due to oral doxycycline’s virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines: Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis. Hepatotoxicity has been reported rarely. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development. (See WARNINGS .) Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of the drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See DOSAGE AND ADMINISTRATION .) Skin: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, fixed drug eruption, skin hyperpigmentation, maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS .) Renal toxicity: Rise in BUN has been reported and is apparently dose related. (See WARNINGS .) Immune: Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms (DRESS), and Jarisch-Herxheimer reaction has been reported in the setting of spirochete infections treated with doxycycline. Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported. Psychiatric: Depression, anxiety, suicidal ideation, insomnia, abnormal dreams, hallucination. Other: Bulging fontanels in infants and intracranial hypertension in adults. (See WARNINGS. ) When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function studies are known to occur. To report SUSPECTED ADVERSE REA...

Additional Listing Data#

Finished product
Yes
Brand name base
Doxycycline Hyclate
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
DOXYCYCLINE HYCLATE100 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
Unii19XTS3T51U
Rxcui1650143

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b4321c75-2e87-4d90-9726-9a28fb2293a3Product name320260112
5e99724e-0654-4aec-b7a2-0b9b10e312eeProduct name320250227
d2d36660-68ce-7e7d-0630-ec4b0d859fadProduct name620220921
a239f4dd-cf93-4660-b190-f97d000f249fProduct name720210607
a9d03566-caeb-4466-8021-74599b048880Product name320210604
12750814-20f7-4f35-b5fa-dbc8811ba858Product name920201007
00a5dbaa-1b7d-4e56-be0c-fedc7bbf5adeProduct name120200706
7b4b06ac-8c50-45f0-9556-293ea558a294Product name120180808
6a5b4392-5ab0-af0d-e0be-47b34e9dbb84Product name520171121
01a4aa74-7e05-63bd-bc10-1b5ceb111371Product name220171115
58b1278c-6dce-49b6-a05e-ea16f389acbaProduct name120160620

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
24658-310-01Doxycycline Hyclate100 in 1 BOTTLETABLET, FILM COATED1001
24658-310-05Doxycycline Hyclate500 in 1 BOTTLETABLET, FILM COATED5001
24658-310-07Doxycycline Hyclate300 in 1 BOTTLETABLET, FILM COATED3001
24658-310-08Doxycycline Hyclate400 in 1 BOTTLETABLET, FILM COATED4001
24658-310-10Doxycycline Hyclate1000 in 1 BOTTLETABLET, FILM COATED10001
24658-310-20Doxycycline Hyclate20 in 1 BOTTLETABLET, FILM COATED201
24658-310-21Doxycycline Hyclate210 in 1 BOTTLETABLET, FILM COATED2101
24658-310-30Doxycycline Hyclate30 in 1 BOTTLETABLET, FILM COATED301
24658-310-50Doxycycline Hyclate50 in 1 BOTTLETABLET, FILM COATED501

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
24658-310-01EA - Each24658-310f1af1755-352b-4da4-ba8d-e561bb9c154f12025-05-14
24658-310-05EA - Each24658-3109cbf5ac4-f021-42c0-98c0-9dfda7a59da012025-05-14
24658-310-07EA - Each24658-3102ea4c030-840f-4125-b7f4-f4c187da7be912025-09-12
24658-310-08EA - Each24658-31065edd7f8-eb3c-415f-9e6e-418c433eddca12025-09-12
24658-310-10EA - Each24658-3104b58ccfb-2560-49b0-9751-97a38cb3992712025-05-14
24658-310-20EA - Each24658-31099caa2bc-cffc-440e-951a-58022a51587112025-05-14
24658-310-21EA - Each24658-31090e699a8-595e-418b-acab-e44a2327f2fd12025-09-12
24658-310-30EA - Each24658-310c0f0e60e-cc2c-4086-bc08-bd506cff586212025-09-12
24658-310-50EA - Each24658-310c9d510e2-5e4a-49ad-b7df-767d411a006812025-05-14

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
24658-310DOXYCYCLINE HYCLATE TABLET, FILM COATED [PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS]1Current NDC, 9 package rows20250418_65cac0b6-3550-48cf-bffa-cf42443c2731.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1650143doxycycline hyclate 100 MG Oral TabletPSN051654c7-8ba6-44f2-842c-72f515e9b32d1
1650143doxycycline hyclate 100 MG Oral TabletPSN65cac0b6-3550-48cf-bffa-cf42443c27311
1650143doxycycline hyclate 100 MG Oral TabletSCD051654c7-8ba6-44f2-842c-72f515e9b32d1
1650143doxycycline hyclate 100 MG Oral TabletSCD65cac0b6-3550-48cf-bffa-cf42443c27311

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
24658-310-0124658031001100 TABLET, FILM COATED in 1 BOTTLE (24658-310-01) 2025-03-07NoNoCurrent
24658-310-0524658031005500 TABLET, FILM COATED in 1 BOTTLE (24658-310-05) 2025-03-07NoNoCurrent
24658-310-0724658031007300 TABLET, FILM COATED in 1 BOTTLE (24658-310-07) 2025-04-14NoNoCurrent
24658-310-0824658031008400 TABLET, FILM COATED in 1 BOTTLE (24658-310-08) 2025-04-14NoNoCurrent
24658-310-10246580310101000 TABLET, FILM COATED in 1 BOTTLE (24658-310-10) 2025-03-07NoNoCurrent
24658-310-202465803102020 TABLET, FILM COATED in 1 BOTTLE (24658-310-20) 2025-03-07NoNoCurrent
24658-310-2124658031021210 TABLET, FILM COATED in 1 BOTTLE (24658-310-21) 2025-04-14NoNoCurrent
24658-310-302465803103030 TABLET, FILM COATED in 1 BOTTLE (24658-310-30) 2025-04-14NoNoCurrent
24658-310-502465803105050 TABLET, FILM COATED in 1 BOTTLE (24658-310-50) 2025-03-07NoNoCurrent